KNC Laboratories Co., Ltd.
KNC Laboratories Co., Ltd. Fundamental Analysis
KNC Laboratories Co., Ltd. (6568.T) shows weak financial fundamentals with a PE ratio of 18.91, profit margin of 5.92%, and ROE of 3.75%. The company generates $8.5B in annual revenue with weak year-over-year growth of -10.66%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 24.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 6568.T's fundamental strength across five key dimensions:
Efficiency Score
Weak6568.T struggles to generate sufficient returns from assets.
Valuation Score
Excellent6568.T trades at attractive valuation levels.
Growth Score
Weak6568.T faces weak or negative growth trends.
Financial Health Score
Excellent6568.T maintains a strong and stable balance sheet.
Profitability Score
Weak6568.T struggles to sustain strong margins.
Key Financial Metrics
Is 6568.T Expensive or Cheap?
P/E Ratio
6568.T trades at 18.91 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 6568.T's PEG of -0.72 indicates potential undervaluation.
Price to Book
The market values KNC Laboratories Co., Ltd. at 0.71 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.62 times EBITDA. This is generally considered low.
How Well Does 6568.T Make Money?
Net Profit Margin
For every $100 in sales, KNC Laboratories Co., Ltd. keeps $5.92 as profit after all expenses.
Operating Margin
Core operations generate 7.08 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.75 in profit for every $100 of shareholder equity.
ROA
KNC Laboratories Co., Ltd. generates $2.34 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
KNC Laboratories Co., Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
KNC Laboratories Co., Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
6568.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
18.91
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.72
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.71
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.12
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.29
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.52
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.04
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 6568.T Stacks Against Its Sector Peers
| Metric | 6568.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 18.91 | 24.08 | Better (Cheaper) |
| ROE | 3.75% | 921.00% | Weak |
| Net Margin | 5.92% | -113338.00% (disorted) | Weak |
| Debt/Equity | 0.29 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 2.52 | 5.09 | Strong Liquidity |
| ROA | 2.34% | -9816.00% (disorted) | Weak |
6568.T outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews KNC Laboratories Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
29.00%
Industry Style: Cyclical, Commodity, Value
High GrowthEPS CAGR
42.37%
Industry Style: Cyclical, Commodity, Value
High GrowthFCF CAGR
3427.55%
Industry Style: Cyclical, Commodity, Value
High Growth